FAQ

ICRF 154

Known as: ICRF-154 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-2013
02419842013

Related topics

Related topics

1 relation

Broader (1)

Razoxin

Related mentions per year

Related mentions per year

1984-2013
19801990200020102020
ICRF 154
Razoxin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II.
ICRF-154 and bimolane have been used for the treatment of cancer, psoriasis, and uveitis in humans. Previous reports have… (More)
Is this relevant?
2001
2001
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
The bisdioxopiperazines ICRF-187 (dexrazoxane), ICRF-193, and ICRF-154 are catalytic noncleavable complex-forming inhibitors of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2000
2000
Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity.
This study investigates the solution thermodynamics of the iron complexes of dexrazoxane (ICRF-187, (+)-1,2-bis(3,5… (More)
Is this relevant?
1997
1997
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines
Histologic and biochemical studies were carried out to compare the protective activity of various bisdiketopiperazines against… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1997
1997
Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis.
The t(7;11)(p15;p15) translocation is an uncommon balanced aberration which has been found predominantly in Orientals, frequently… (More)
Is this relevant?
1995
1995
A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
A series of twelve structurally related bisdioxopiperazines that included ICRF-187 (dexrazoxane), ICRF-159 (razoxane), ICRF-193… (More)
Is this relevant?
Highly Cited
1991
Highly Cited
1991
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Several recently developed derivatives of bis(2,6-dioxopiperazine) have been shown to be new antitumor agents and are currently… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1991
1991
Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
In the accompanying paper (K. Tanabe, Y. Ikegami, R. Ishida, and T. Andoh, Cancer Res., 51: 4903-4908, 1991), we showed that ICRF… (More)
Is this relevant?
1985
1985
Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.
Comparisons were made of the protective activity of ICRF-187 and a series of related bis-dioxopiperazine analogues against acute… (More)
Is this relevant?
1984
1984
Bimolane: structure determination indicates anticancer activity is attributable to ICRF-154.
X-ray diffraction studies of crystals from samples of bimolane synthesized in China and in the United States showed that the… (More)
Is this relevant?